<DOC>
	<DOCNO>NCT00004147</DOCNO>
	<brief_summary>RATIONALE : COL-3 may stop growth brain tumor stop blood flow tumor . PURPOSE : Phase I/II trial study effectiveness COL-3 treating patient progressive recurrent brain tumor follow radiation therapy chemotherapy .</brief_summary>
	<brief_title>COL-3 Treating Patients With Progressive Recurrent Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , dose limit toxicity , safety profile oral COL-3 alone combine anticonvulsant know metabolized CYP450 patient progressive recurrent high grade anaplastic astrocytoma , anaplastic oligodendroglioma , glioblastoma multiforme . - Define pharmacokinetics pharmacodynamics COL-3 schedule determine effect hepatic enzyme induce drug , anticonvulsant , pharmacokinetics . - Determine response rate , disease free survival , survival patient treat regimen . OUTLINE : This dose-escalation , multicenter study COL-3 . Patients stratify anticonvulsant ( anticonvulsant cause induction CYP450 v anticonvulsant cause modest induction CYP450 anticonvulsant ) . - Phase I : Patients receive oral COL-3 daily . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos COL-3 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . - Phase II : Patients receive oral COL-3 daily MTD phase I portion study . Patients follow every 2 month death . PROJECTED ACCRUAL : A total 15-18 patient accrued phase I study total 35 patient accrue phase II study rate 3 patient per month .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven high grade glioma progressive recurrent follow radiotherapy chemotherapy Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Prior low grade glioma progress high grade glioma follow radiotherapy and/or chemotherapy allow Measurable disease MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal SGOT SGPT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No myocardial infarction , stroke , congestive heart failure within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study No serious active infection medical illness would preclude compliance HIV negative No history gastrointestinal disorder would interfere absorption study drug No malignancy within past 5 year except curatively treat carcinoma situ cervix breast , basal cell squamous cell skin cancer No hypersensitivity tetracyclines derivative PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since prior nitrosoureas ) recover No 2 prior chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : No prior large field radiotherapy ( great 20 % total bone marrow ) At least 3 month since prior radiotherapy recover Surgery : No prior major upper gastrointestinal surgery At least 14 day since prior major surgery Other : No concurrent investigational agent No prolonged sun exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>